Investment in Biopharma Facilities Continues

Many new facilities are designed for flexibility, combined with low-cost, highly efficient manufacturing

By Andrew Ferraro, That’s Nice LLC / Nice Insight

3 of 3 1 | 2 | 3 > View on one page

Recent and ongoing biopharmaceutical CDMO investments include:
• Samsung Biologics is investing $740 million in a new biologics manufacturing facility that will double its production capacity. The plant is located in South Korea and expected to be onstream in 2018.

• Brammer Bio, which was formed in late March 2016 when Brammer Biopharmaceuticals merged with Florida Biologix to create a cell and gene therapy biologics CDMO, now has 45,000 ft2 of process development and phase I/II clinical manufacturing space in Alachua, FL, and is developing a 50,000 ft2 facility in Lexington, MA, with plans to build-out large-scale, phase III/commercial-ready viral vector manufacturing suites and segregated cell and gene therapy suites for clinical and commercial launch services.

• WuXi PharmaTech is constructing its third cGMP facility for the manufacture of cell therapy products. When operational in mid-2016, the Philadelphia plant will produce cell therapies that contain viral vectors, such as chimeric antigen receptor T cell (CAR T cell) therapies. The second facility for autologous cell-based therapeutics was completed in 2015. The company is also building a state-of-the-art integrated biologics solution center at its headquarters in Shanghai to support biologics discovery, development and clinical manufacturing.

• Catalent Pharma Solutions opened its new, state-of-the-art biomanufacturing Center of Excellence in Madison, WI, in April 2013.

• Abbvie is investing $320 million to build a facility in Singapore for the production of both small-molecule and biologic APIs. The company will also spend $30 million to expand its Barceloneta, Puerto Rico, site.

• Patheon Biologics is adding capacity at its sites in the U.S. and the Netherlands.

• KBI Biopharma is expanding its mammalian and microbial API production capacity.

• Fujifilm Diosynth Biotechnologies acquired Kalon Biotherapeutics in 2014 and has since made additional investments to increase its bioreactor capacity and expand its process and analytical development capabilities, which are coming online in 2016.

To learn more about Nice Insight contact Andrew at andrew@thatsnice.com or visit www.niceinsight.com and the annual study websites: clinical services at www.niceinsightcro.com, contract development and manufacturing atwww.niceinsightcdmo.com, pharmaceutical excipients suppliers at www. niceinsightexcipients.com and pharmaceutical equipment (products, systems and services) at www.niceinsightpharmaequipment.com.

REFERENCES
1. BioPlan Associates Inc. “Top 15 Trends in Biopharmaceutical Manufacturing,” Contract Pharma, Sept. 11, 2015.
2. Otto, R., Santagostino, A., and Schrader, U. “Rapid growth in biopharma: Challenges and opportunities,” December 2014. http://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/rapid-growth-in-biopharma.
3. That’s Nice. The 2016 Nice Insight Contract Development & Manufacturing Survey, January 2016.
4. W. Downey, “Biopharmaceutical Contract Manufacturing Capacity Expansions”, Contract Pharma, June 2, 2015. http://www.contractpharma.com/issues/2015-06-01/view_features/biopharmaceutical-contract-manufacturing-capacity-expansions
5. Roots Analysis, “Biopharmaceutical Contract Manufacturing Market, 2015 - 2025”, Press Release, May 5, 2015; http://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market-2015-2025/92.html
6. R. Hernandez, “Top Trends in Biopharmaceutical Manufacturing: 2015,” Pharmaceutical Technology, Volume 39, Issue 6, Jun 02, 2015
7. N. Khan, GE Ships Ready-Made Drug Factories From Berlin to Beijing, Bloomberg, November 1 2015. http://www.bloomberg.com/news/articles/2015-11-01/ge-ships-ready-made-drug-factories-from-berlin-to-beijing.

 

3 of 3 1 | 2 | 3 > View on one page
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments